Abstracts tagged "systemic lupus erythematosus (SLE) and biomarkers"

Abstract Number: 1034 • 2019 ACR/ARP Annual Meeting
Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus
Carlos Perez-Sanchez¹, Irene Cecchi ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ⁴, Nuria Barbarroja ⁵, Maria Luque-Tevar ⁴, Alejandro Ibañez-Costa ⁴, Ivan Arias de la Rosa ⁶, Maria del Carmen Abalos-Aguilera ⁴, Rafaela Ortega ⁴, Alejandro Escudero ⁷, Massimo Radin ², Savino Sciascia ⁸, Mª Ángeles Aguirre-Zamorano ⁷, Eduardo Collantes-Estevez ⁶ and Chary Lopez-Pedrera ⁴, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²University of Turin, Turin, Italy, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: Recent studies have highlighted the potential role of microRNAs (miRNAs) as diagnostic and prognostic biomarkers in Systemic Lupus Erythematosus (SLE). While Rituximab (RTX) represents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].